

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

AC16 [Human hybrid cardiomyocyte]

RRID:CVCL_4U18

Type: Cell Line

Proper Citation

Millipore Cat# SCC109, RRID:CVCL_4U18

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4U18

Proper Citation: Millipore Cat# SCC109, RRID:CVCL_4U18

Description: Cell line AC16 [Human hybrid cardiomyocyte] is a Hybrid cell line with a species of origin Homo sapiens (Human)

Defining Citation: [PMID:15913645](#)

Comments: Characteristics: Can differentiate when cultured in mitogen-free medium. The cells may be used to study developmental regulation of cardiomyocytes (Millipore=SCC109)., Characteristics: Hybrid of adult ventricular cardiomyocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645)., Group: Patented cell line.

Category: Hybrid cell line

Organism: Homo sapiens (Human)

Name: AC16 [Human hybrid cardiomyocyte]

Cross References: EFO:EFO_0022630, ATCC:CRL-3568, CLS:305215, Millipore:SCC109, Wikidata:Q54607923

ID: CVCL_4U18

Vendor: Millipore

Catalog Number: SCC109

Hierarchy: cvcl_4u14

Record Creation Time: 20250130T070153+0000

Record Last Update: 20260904T020612+0000

Ratings and Alerts

No rating or validation information has been found for AC16 [Human hybrid cardiomyocyte].

Warning: Discontinued: ATCC; PTA-1500

Characteristics: Can differentiate when cultured in mitogen-free medium. The cells may be used to study developmental regulation of cardiomyocytes (Millipore=SCC109).,

Characteristics: Hybrid of adult ventricular cardiomyocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645)., Group: Patented cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 332 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li B, et al. (2026) Modulation of Ferroptosis by the Irx3-Etfa Pathway Protects Against Cardiac Hypertrophy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(3), e71524.

Jing G, et al. (2026) Plasma exosomal miR-339-3p promotes myocardial remodeling in chronic heart failure by regulating USP25-mediated DDX58 deubiquitination. Journal of cell communication and signaling, 20(3), e70090.

He Y, et al. (2026) Exosomal lncRNA FENDRR Orchestrates Immune Remodelling and Ferroptosis in the Comorbidity of Lung Cancer and Type 1 Myocardial Infarction. Human mutation, 2026, 8861747.

Wang Q, et al. (2026) Targeting ferroptosis with chenodeoxycholic acid improves residual cardiac dysfunction after surgical ventricular reconstruction. British journal of pharmacology.

Zhang ZH, et al. (2026) 4-Methylcatechol attenuates diabetic myocardial disorder via the ESR1-PI3K-AKT pathway. Frontiers in pharmacology, 17, 1801465.

Zhang Z, et al. (2026) High sucralose exposure in early pregnancy increases the susceptibility of heart defects in mice offspring. iScience, 29(5), 115603.

Zhou Y, et al. (2026) Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)-mediated H4K16 lactylation-driven inflammation. British journal of pharmacology, 183(15), 4364.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. Molecular cancer research : MCR, 24(1), 60.

Elia A, et al. (2026) Amyloid ? Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(20), e11924.

Mittal A, et al. (2026) Evolutionary-guided advanced deep-learning architecture powers mammalian GPCRome agonist predictions. *Cell reports*, 45(3), 117003.

Alamillo L, et al. (2026) Protocol to measure protein half-life in cell culture using heavy water. *STAR protocols*, 7(1), 104426.

Audebrand A, et al. (2026) Second-generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy-induced toxicity. *British journal of pharmacology*, 183(12), 3377.

Zhang Y, et al. (2026) Cargo-defined engineered vesicles enable targeted miRNA delivery for cardiac repair after myocardial infarction. *Biomaterials*, 334, 124251.

Yang Y, et al. (2026) S100A8/S100A9 Links Diabetic Stress to Cardiac Progenitor Cell Dysfunction and Fibrotic Heart Failure: An Integrated Transcriptomic, Single-Cell, and Functional Study. *Human mutation*, 2026, 1662522.

Liu XQ, et al. (2025) De novo assembly of nuclear stress bodies rearranges and enhances NFIL3 to restrain acute inflammatory responses. *Cell*, 188(17), 4586.

Guthormsen J, et al. (2025) Cardiomyocyte overexpression of microRNA-210 mitigates apoptotic cell death induced by doxorubicin. *Cardio-oncology* (London, England), 12(1), 18.

De Bartolo A, et al. (2025) A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of Fc γ RIIA receptor. *Acta pharmacologica Sinica*, 46(3), 618.

Dorji JP, et al. (2025) c-MYC mRNA destabilization inhibited lethal pancreatic cancer in vivo with significant survival outcomes. *Frontiers in pharmacology*, 16, 1630476.

Alamillo L, et al. (2025) Deuterium labeling enables proteome-wide turnover kinetics analysis in cell culture. *Cell reports methods*, 5(7), 101104.

Dong X, et al. (2025) Identification of novel PTP1B inhibitor for the treatment of LPS-induced myocardial apoptosis: machine learning based virtual screening and biological evaluation. *Journal of enzyme inhibition and medicinal chemistry*, 40(1), 2596950.